31st Oct 2014 07:00
Annual General Meeting
31 October 2014 - Clinigen Group plc (AIM: CLIN, "Clinigen", the "Group"), the global specialty pharmaceuticals and services company announces that at the Annual General Meeting, held on 30 October 2014, all resolutions were duly passed.
The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.clinigengroup.com.
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Peter George, Group Chief Executive Officer | |
Robin Sibson, Chief Financial Officer | |
Numis Securities Limited - Nominated adviser & Joint Broker | Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) | |
James Black/Tom Ballard (Corporate Broking) | |
|
|
Peel Hunt LLP - Joint Broker | Tel: +44 (0) 20 7418 8900 |
James Steel / Jock Maxwell Macdonald |
|
Instinctif Partners - Media Relations | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/Jen Lewis / Emma Barlow | Email: [email protected] |
About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. Listed at The London Stock Exchange AIM, the Group has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. Clinigen CTS sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. Clinigen GAP specializes in the consultancy, development, management and implementation of programs, providing global access for patients and their clinicians to drugs not available in their markets. For more information, please visit www.clinigengroup.com.
Related Shares:
CLIN.L